{"id":"peginterferon-alfa-2-a","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-50","effect":"Headache"},{"rate":"20-30","effect":"Depression and mood disorders"},{"rate":"10-25","effect":"Neutropenia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"10-20","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Peginterferon alfa-2a is a long-acting form of interferon-alpha created by conjugating polyethylene glycol (PEG) to interferon alfa-2a, which extends its half-life and duration of action. It binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral genes, enhance natural killer cell activity, and promote apoptosis in infected or malignant cells. This mechanism makes it effective against chronic viral infections and certain malignancies.","oneSentence":"Peginterferon alfa-2a is a pegylated interferon that activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:57.930Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"},{"name":"Chronic hepatitis B virus infection"},{"name":"Melanoma (adjuvant therapy)"}]},"trialDetails":[{"nctId":"NCT00630058","phase":"PHASE1","title":"A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2008-04","conditions":"Hepatitis C","enrollment":20},{"nctId":"NCT02201459","phase":"PHASE3","title":"Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-08","conditions":"Chronic Myeloid Leukemia","enrollment":200},{"nctId":"NCT06707922","phase":"NA","title":"A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"ENROLLING_BY_INVITATION","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2022-03-18","conditions":"Chronic Hepatitis B","enrollment":350},{"nctId":"NCT03852433","phase":"PHASE2","title":"Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-31","conditions":"Chronic Hepatitis Delta","enrollment":175},{"nctId":"NCT04412863","phase":"PHASE2","title":"Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2020-07-03","conditions":"Chronic Hepatitis B","enrollment":84},{"nctId":"NCT04846491","phase":"PHASE3","title":"A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2019-12-04","conditions":"Chronic Hepatitis B","enrollment":475},{"nctId":"NCT04640129","phase":"PHASE4","title":"HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir.","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-01-01","conditions":"Liver Fibrosis","enrollment":336},{"nctId":"NCT05941845","phase":"PHASE2","title":"Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-07-24","conditions":"Membranous Nephropathy","enrollment":5},{"nctId":"NCT05928000","phase":"","title":"HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2023-05-01","conditions":"Hepatitis D","enrollment":80},{"nctId":"NCT01369212","phase":"PHASE3","title":"Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2012-11","conditions":"Hepatitis B","enrollment":201},{"nctId":"NCT03719313","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2018-12-01","conditions":"Hepatitis Delta Virus","enrollment":407},{"nctId":"NCT02430181","phase":"PHASE2","title":"Lonafarnib With and Without Ritonavir in HDV (LOWR-1)","status":"COMPLETED","sponsor":"Eiger BioPharmaceuticals","startDate":"2014-11","conditions":"Chronic Hepatitis D Infection","enrollment":21},{"nctId":"NCT01023035","phase":"PHASE3","title":"Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-07","conditions":"Hepatitis C, Chronic","enrollment":687},{"nctId":"NCT02263079","phase":"PHASE3","title":"A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-06-16","conditions":"Pediatric Immuno-Tolerant Chronic Hepatitis B","enrollment":62},{"nctId":"NCT04517539","phase":"PHASE2","title":"Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors","status":"UNKNOWN","sponsor":"Shanghai Cancer Hospital, China","startDate":"2020-12-01","conditions":"Thymic Epithelial Tumor","enrollment":65},{"nctId":"NCT03552549","phase":"PHASE2, PHASE3","title":"SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-08-05","conditions":"Melanoma","enrollment":126},{"nctId":"NCT01088659","phase":"PHASE3","title":"A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-16","conditions":"Hepatitis D, Chronic","enrollment":50},{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT01429792","phase":"PHASE4","title":"A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09-25","conditions":"Hepatitis C, Chronic","enrollment":1013},{"nctId":"NCT01889433","phase":"PHASE3","title":"An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Biocad","startDate":"2013-07-10","conditions":"Hepatitis, Hepatitis C","enrollment":170},{"nctId":"NCT01033448","phase":"PHASE4","title":"A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Hepatitis C, Chronic","enrollment":59},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00423670","phase":"PHASE2","title":"Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03523)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01","conditions":"Chronic Hepatitis C","enrollment":765},{"nctId":"NCT00684268","phase":"PHASE2","title":"Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":"Hepatitis C","enrollment":70},{"nctId":"NCT00467077","phase":"PHASE2","title":"Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer","status":"TERMINATED","sponsor":"California Cancer Consortium","startDate":"2004-09","conditions":"Kidney Cancer","enrollment":21},{"nctId":"NCT00861406","phase":"PHASE1","title":"Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-10","conditions":"Melanoma","enrollment":38},{"nctId":"NCT01628692","phase":"PHASE2","title":"Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus","enrollment":230},{"nctId":"NCT02118597","phase":"","title":"An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2014-05","conditions":"Hepatitis C, Chronic","enrollment":19},{"nctId":"NCT01285050","phase":"PHASE4","title":"Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2011-01","conditions":"HIV Infection, Hepatitis C","enrollment":20},{"nctId":"NCT01258101","phase":"PHASE4","title":"A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-05","conditions":"Hepatitis C, Chronic","enrollment":395},{"nctId":"NCT00700401","phase":"","title":"POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11","conditions":"Hepatitis C, Chronic","enrollment":262},{"nctId":"NCT00522249","phase":"PHASE1, PHASE2","title":"Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2007-05","conditions":"Carcinoma, Renal Cell","enrollment":10},{"nctId":"NCT01471574","phase":"PHASE3","title":"Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C, Genotype 1","enrollment":549},{"nctId":"NCT00160251","phase":"PHASE2","title":"Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":"Chronic Hepatitis C","enrollment":357},{"nctId":"NCT01170962","phase":"PHASE2","title":"Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-08","conditions":"Hepatitis C Virus","enrollment":512},{"nctId":"NCT01448044","phase":"PHASE3","title":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Hepatitis C","enrollment":152},{"nctId":"NCT01718158","phase":"PHASE3","title":"Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01","conditions":"Hepatitis C","enrollment":444},{"nctId":"NCT01616524","phase":"PHASE3","title":"Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-07","conditions":"Hepatitis C Virus (HCV)","enrollment":880},{"nctId":"NCT01581203","phase":"PHASE3","title":"Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-05","conditions":"Hepatitis C Virus","enrollment":748},{"nctId":"NCT02112630","phase":"NA","title":"Boceprevir in End Stage Renal Disease (ESRD)","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2013-05","conditions":"Hepatitis C Infection, End Stage Renal Disease","enrollment":""},{"nctId":"NCT00633230","phase":"PHASE1","title":"Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"","conditions":"Hepatitis C Virus","enrollment":""},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT01459913","phase":"PHASE3","title":"Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2011-11","conditions":"Hepatitis C, Chronic","enrollment":239},{"nctId":"NCT00797745","phase":"PHASE2","title":"A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-11","conditions":"Hepatitis C, Chronic","enrollment":111},{"nctId":"NCT02339337","phase":"PHASE4","title":"A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2010-06","conditions":"HBV/HCV Co-infection","enrollment":203},{"nctId":"NCT01405027","phase":"PHASE4","title":"Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy","status":"COMPLETED","sponsor":"Chronic Liver Disease Foundation","startDate":"2011-12","conditions":"Chronic Hepatitis C, Genotype 1","enrollment":197},{"nctId":"NCT01335529","phase":"PHASE2","title":"Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-05","conditions":"HCV Coinfection, HIV-1 Infection","enrollment":69},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT01808248","phase":"PHASE2","title":"Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-02","conditions":"Hepatitis C","enrollment":47},{"nctId":"NCT00627926","phase":"PHASE3","title":"A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2008-03","conditions":"Hepatitis C","enrollment":1095},{"nctId":"NCT00535847","phase":"PHASE2","title":"A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-10","conditions":"Hepatitis C","enrollment":117},{"nctId":"NCT00420784","phase":"PHASE2","title":"A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2007-02","conditions":"Hepatitis C","enrollment":465},{"nctId":"NCT00372385","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-08","conditions":"Chronic Hepatitis C","enrollment":334},{"nctId":"NCT00336479","phase":"PHASE2","title":"Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2006-06","conditions":"Chronic Hepatitis C","enrollment":263},{"nctId":"NCT01371578","phase":"PHASE2","title":"Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":163},{"nctId":"NCT01271790","phase":"PHASE2","title":"A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Hepatitis C, Chronic","enrollment":245},{"nctId":"NCT01384383","phase":"PHASE2","title":"GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2011-08","conditions":"Chronic Hepatitis C","enrollment":248},{"nctId":"NCT01356160","phase":"PHASE2","title":"GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":351},{"nctId":"NCT01225380","phase":"PHASE2","title":"A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-10","conditions":"Chronic Hepatitis C Infection","enrollment":324},{"nctId":"NCT00056862","phase":"PHASE4","title":"Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2003-03","conditions":"Hepatitis C","enrollment":58},{"nctId":"NCT00743795","phase":"PHASE2","title":"Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-10","conditions":"HCV Infection","enrollment":252},{"nctId":"NCT00580801","phase":"PHASE2","title":"An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec BVBA","startDate":"2008-01","conditions":"Hepatitis C","enrollment":24},{"nctId":"NCT00720434","phase":"PHASE2","title":"A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-08","conditions":"Hepatitis C","enrollment":35},{"nctId":"NCT00402428","phase":"PHASE3","title":"Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2006-12","conditions":"Chronic Hepatitis C","enrollment":1331},{"nctId":"NCT00411385","phase":"PHASE3","title":"Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2007-02","conditions":"Chronic Hepatitis C","enrollment":933},{"nctId":"NCT00136318","phase":"PHASE3","title":"Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2004-01","conditions":"Depression","enrollment":208},{"nctId":"NCT00367887","phase":"PHASE2","title":"A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-10","conditions":"Hepatitis C","enrollment":246},{"nctId":"NCT01140997","phase":"PHASE2","title":"Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2010-07","conditions":"Chronic Hepatitis C","enrollment":211},{"nctId":"NCT01623336","phase":"PHASE2, PHASE3","title":"BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C","status":"UNKNOWN","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2012-01","conditions":"Chronic Hepatitis C","enrollment":740},{"nctId":"NCT00830609","phase":"PHASE4","title":"High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3","status":"COMPLETED","sponsor":"Dr. Conrado Fernandez","startDate":"2008-11","conditions":"Chronic Hepatitis C","enrollment":101},{"nctId":"NCT01447394","phase":"PHASE3","title":"Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-03","conditions":"Hepatitis C Virus (HCV)","enrollment":""},{"nctId":"NCT01343186","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2011-01","conditions":"Healthy Subjects","enrollment":39},{"nctId":"NCT01464281","phase":"NA","title":"A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2011-10","conditions":"Chronic Hepatitis B","enrollment":300},{"nctId":"NCT00553930","phase":"PHASE4","title":"Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients","status":"COMPLETED","sponsor":"Sociedad Andaluza de Enfermedades Infecciosas","startDate":"2007-11","conditions":"Hepatitis C, Chronic, HIV Infections","enrollment":71},{"nctId":"NCT00491179","phase":"PHASE4","title":"Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2006-06","conditions":"Chronic Hepatitis C, Hemodialysis","enrollment":35},{"nctId":"NCT00332176","phase":"PHASE2","title":"A Study to Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"BioWest Therapeutics Inc","startDate":"2006-06","conditions":"Chronic Hepatitis C","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegasys"],"phase":"marketed","status":"active","brandName":"Peginterferon alfa 2 A","genericName":"Peginterferon alfa 2 A","companyName":"Dr. Conrado Fernandez","companyId":"dr-conrado-fernandez","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peginterferon alfa-2a is a pegylated interferon that activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity. Used for Chronic hepatitis C virus infection, Chronic hepatitis B virus infection, Melanoma (adjuvant therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}